DGAP-News: Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec and Harvard University to collaborate on exploration of
enteroendocrine signals affecting key metabolic pathways
10.10.2013 / 07:31
---------------------------------------------------------------------
Hamburg, Germany - 10 October 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced a second research
collaboration, TargetEEM (Enteroendocrine Mechanisms), with the laboratory
of Doug Melton, Xander University Professor in the Department of Stem Cell
and Regenerative Biology at Harvard University, Harvard Stem Cell Institute
Scientific Co-Director and Howard Hughes Medical Institute Investigator.
The objective of this collaboration is to identify novel enteroendocrine
mechanisms, pathways and signals regulating key metabolic processes that
have disease-modifying potential in diabetic patients. Evotec's first
collaboration with the Melton laboratory was focused on beta cell
replication.
Type 2 diabetes is a disease affecting several hundred million people
worldwide. Although treatment regimes based on insulin and insulin
sensitizers are the standard of care and have helped patients tremendously,
they are not modifying cause or progression of the disease.
TargetEEM is comprehensive screening effort by Harvard and Evotec designed
to systematically search for novel pathways and targets that have the
potential to address key pathophysiological mechanisms involved in insulin
resistance and energy handling.
The basis of this effort will be disease-relevant animal models as well as
unbiased transcriptional and proteomic profiling platforms contributed by
both collaboration partners. Harvard and Evotec will collaborate in a
highly integrated and fashion and share potential commercial rewards.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: 'Metabolic
diseases and in particular diabetes continue to be on the rise and are not
only a serious threat to patients but represent enormous challenges to
healthcare systems all over the world. We are very excited about this
second collaboration with Doug's lab. It is designed to break new ground
and identify novel enteroendocrine mechanisms with disease-modifying
potential.'
'This collaboration between Harvard and Evotec, the second in the field of
metabolic disease, benefits from our good working relationship and mutual
interest in undertaking a comprehensive effort to elucidate the disease
mechanisms that underlie this serious health problem', added Dr Vivian
Berlin, Director Business Development in Harvard's Office of Technology
Development.
Financial details were not disclosed.
ABOUT DIABETES MELLITUS
Diabetes Mellitus is a chronic incapacitating disease associated with
severe life-long conditions such as cardiovascular diseases, kidney
diseases, nerve damage and eye diseases, which require intensive monitoring
and control. Diabetes is caused by relative or complete decrease in insulin
production and secretion by pancreatic beta cells. Furthermore, diabetes
can be caused by the reduced effectiveness of secreted insulin in
consequence of the gradual loss of insulin sensitivity of target cells
which is called insulin resistance. At present, there is no cure for
diabetes and only symptomatic treatment options are available. The most
common diabetes types are type 1 and type 2 diabetes. Currently, about
90-95% of diabetes patients worldwide have type 2 diabetes. According to
the International Diabetes Foundation, there are 371 million people
worldwide who are diagnosed with diabetes (2011: 366 million) and about 187
million who are at risk of costly and debilitating diabetes complications
who have not yet been diagnosed. It is estimated that about 4.8 million
people will have died from diabetes at the end of 2012 (2011: 4.0 million).
Concerning the diabetes market volume, $ 471 bn were spent on the treatment
of diabetes in 2012 (2011: $ 465 bn).
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
ABOUT HARVARD UNIVERSITY'S OFFICE OF TECHNOLOGY DEVELOPMENT
Harvard's Office of Technology Development ('OTD') is responsible for all
activities pertaining to the evaluation, patenting and licensing of new
inventions and discoveries made at Harvard University and Harvard Medical
School. OTD also serves to further the development of Harvard technologies
through the establishment of sponsored research collaborations with
industry. OTD's mission is to promote the public good by fostering
innovation and translating new inventions made at Harvard into useful
products available and beneficial to society.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
10.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
234010 10.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 304528
Anzahl Zeichen: 10153
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 313 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
